B
bekeero
Guest
This is an answer from the manufacturer of the cream when asked what is the difference between Baricitnib and Decernotinib and Ruxolitinib and Tofacitinib /
Hi,
1) baricitinib – “Despite widespread expectations that the FDA would approve baricitinib for RA, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety.”
2) decernotinib – not approved in FDA(The application was not left), and i not saw any research about that, everything is in the initial stage, but I hope that this will be useful
FDA APPROVED TOFACITINIB AND RUXOLITINIB ONLY!
Difirent of which JAK subtypes they inhibit:
TOFA JAK1 and JAK3
RUXO JAK1 and JAK2
Hi,
1) baricitinib – “Despite widespread expectations that the FDA would approve baricitinib for RA, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety.”
2) decernotinib – not approved in FDA(The application was not left), and i not saw any research about that, everything is in the initial stage, but I hope that this will be useful
FDA APPROVED TOFACITINIB AND RUXOLITINIB ONLY!
Difirent of which JAK subtypes they inhibit:
TOFA JAK1 and JAK3
RUXO JAK1 and JAK2